Aptevo Therapeutics
APVO
NASDAQ
IPO2016
about APVO
Aptevo Therapeutics is a biotechnology company dedicated to developing innovative treatments for diseases such as cancer and blood disorders, with its lead product being pegilodecakin (LYS), an enzyme that enhances chemotherapy effectiveness in treating solid tumors.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $5.04 | $5.17 | $3.95 | $5.19M | 181.33K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$2.23 | n/a | n/a | 0% | 0% | 0% |